CytoAgents, Quotient Sciences to take COVID-19 drug candidate GP1681 into human trials
US biotech company CytoAgents has joined forces with CDMO and CRO services provider Quotient Sciences to accelerate the development of its COVID-19 drug candidate GP1681 into human clinical trials for the treatment of cytokine storm. According to the partners, scientific consensus is building that severe illness resulting from COVID-19 and other infectious diseases is triggered by […]